News Celgene signs brace of immuno-oncology deals with US biotech... Despite a looming takeover by Bristol-Myers Squibb, Celgene hasn’t stopped making pipeline-boosting deals.
Oncology Unlocking the future of epigenetics, with Carlos Buesa Carlos Buesa, CEO of Oryzon Genomics, discusses exploring how epigenetics is reshaping the landscape of oncology and CNS therapies.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
